Madrigal Pharmaceuticals shares were higher on April 1, 2026, with trading interest centered on sustained confidence in the company’s commercial trajectory for Rezdiffra, its MASH therapy. The stock’s move follows a period of heightened attention on Rezdiffra’s rapid uptake and the company’s messaging that 2026 net sales growth should be supported by broader first-line access and continued disease awareness momentum.

The latest reported full-year 2025 results underscored the scale of the launch: Rezdiffra net sales totaled $958.4 million in 2025, with quarterly sales in Q4 reaching $321.1 million and patient counts exceeding 36,000 by period-end. Management has also discussed that payer contracting for 2026 is aimed at maintaining broad first-line access with minimal utilization hurdles, even as gross-to-net dynamics are expected to rise versus 2025 due to updated payer agreements.

MDGL has a relatively elevated short interest for a large-cap biotech, creating conditions where incremental buying can have an outsized effect on daily price action. Recent short-interest data showed about 3.74 million shares sold short, roughly 20.8% of the public float, implying that positive sentiment or fresh flows into the name can pressure short positions and add volatility to upside moves.

Near-term attention remains on ongoing Rezdiffra commercial execution (new starts, persistence, and payer mix), plus pipeline progress designed to extend the franchise in MASH. Investors are also watching the cadence of clinical and regulatory updates aimed at longer-term label expansion opportunities, including compensated cirrhosis (F4c) development, which the company has positioned as a potentially meaningful market expansion.